Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial

被引：0

作者：

Pressiani, T. ^{[1
]}

Balsano, R. ^{[2
]}

Giordano, L. ^{[3
]}

Milella, M. ^{[4
,5
]}

Bergamo, F. ^{[6
]}

Bozzarelli, S. ^{[7
]}

Noventa, S. ^{[8
]}

Ferrari, D. ^{[9
]}

Scartozzi, M. ^{[10
,11
]}

Parra, H. J. Soto ^{[12
]}

Auriemma, A. ^{[4
,5
]}

Solda, C. ^{[13
]}

Zaniboni, A. ^{[8
]}

Zecchetto, C. ^{[4
,5
]}

Rizzato, M. D. ^{[6
]}

Rimassa, L. ^{[14
]}

Santoro, A. ^{[15
]}

机构：

[1] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy

[2] Humanitas Univ, IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Dept Biomed Sci,Humanitas Canc Ctr, Rozzano, Italy

[3] IRCSS Humanitas Res Hosp, Biostat Unit, Humanitas Canc Ctr, Rozzano, Italy

[4] Univ Verona, Sect Innovat Biomed, Dept Engn Innovat Med DIMI, Oncol Area, Verona, Italy

[5] Verona Univ & Hosp Trust, Verona, Italy

[6] IRCCS, Veneto Inst Oncol IOV, Dept Oncol, Oncol 1, Padua, Italy

[7] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy

[8] Fdn Poliambulanza Ist Osped, Med Oncol Unit, Brescia, Italy

[9] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol Dept, Med Oncol & Hematol Unit,AO S Paolo, Milan, Italy

[10] Univ Monserrato, Med Oncol, Monserrato, Italy

[11] Univ Hosp, Monserrato, Italy

[12] Azienda Osped Univ Policlin San Marco, Oncol Med, Catania, Italy

[13] IRCCS, Veneto Inst Oncol IOV, Oncol 1, Dept Oncol, Padua, Italy

[14] Humanitas Univ, Med Oncol & Hematol Unit, Dept Biomed Sci, Humanitas Canc Ctr,IRCCS Humanitas Res Hosp, Rozzano, Italy

[15] Humanitas Univ, Med Oncol & Hematol Unit, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Rozzano, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

285P

引用

页码：S120 / S120

页数：1

共 50 条

[41] Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial
Wei, Jing
Zhang, Pengfei
Hu, Qiancheng
Cheng, Xiaolong
Shen, Chaoyong
Chen, Zhixin
Zhuang, Wen
Yin, Yuan
Zhang, Bo
Gou, Hongfeng
Yang, Kun
Bi, Feng
Liu, Ming
FRONTIERS IN IMMUNOLOGY, 2025, 16
[42] Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma
Ajjai Alva
Stephanie Daignault
David C. Smith
Maha Hussain
Investigational New Drugs, 2014, 32 : 188 - 194
[43] Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial
Xu, Ling-Xiao
Yuan, Jia-Jia
Xue, Ran
Zhou, Jun
WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (30)
[44] Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
Chen Chang
Xiaofen Li
Dan Cao
BMC Cancer, 21
[45] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
Shui, Lin
Cheng, Ke
Li, Xiaofen
Shui, Pixian
Zhou, Xiaohan
Li, Jian
Yi, Cheng
Cao, Dan
BMC CANCER, 2020, 20 (01)
[46] Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
Chang, Chen
Li, Xiaofen
Cao, Dan
BMC CANCER, 2021, 21 (01)
[47] A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer
Hyun Jung Kim
Nam Su Lee
Sang-Cheol Lee
Sang Byung Bae
Chan Kyu Kim
Young Gook Cheon
Young Seok Kim
Jong Ho Moon
Young Deok Cho
Sang Heum Park
Kyu Taek Lee
Sung Kyu Park
Jong-Ho Won
Hee Sook Park
Dae Sik Hong
Cancer Chemotherapy and Pharmacology, 2009, 64 : 371 - 377
[48] Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma
Alva, Ajjai
Daignault, Stephanie
Smith, David C.
Hussain, Maha
INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 188 - 194
[49] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
Lin Shui
Ke Cheng
Xiaofen Li
Pixian Shui
Xiaohan Zhou
Jian Li
Cheng Yi
Dan Cao
BMC Cancer, 20
[50] A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer
Kim, Hyun Jung
Lee, Nam Su
Lee, Sang-Cheol
Bae, Sang Byung
Kim, Chan Kyu
Cheon, Young Gook
Kim, Young Seok
Moon, Jong Ho
Cho, Young Deok
Park, Sang Heum
Lee, Kyu Taek
Park, Sung Kyu
Won, Jong-Ho
Park, Hee Sook
Hong, Dae Sik
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 371 - 377

← 1 2 3 4 5 →